

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 18, 2025

J82

RRID:CVCL_0359

Type: Cell Line

Proper Citation

(RRID:CVCL_0359)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0359

Proper Citation: (RRID:CVCL_0359)

Sex: Male

Defining Citation: [PMID:77569](#), [PMID:571047](#), [PMID:687519](#), [PMID:833871](#), [PMID:864752](#), [PMID:870558](#), [PMID:2594029](#), [PMID:3413074](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:4057431](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6823318](#), [PMID:7787250](#), [PMID:8077054](#), [PMID:9137463](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12127398](#), [PMID:14762065](#), [PMID:15846775](#), [PMID:16885334](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25997541](#), [PMID:26589293](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Population: Caucasian; Swedish., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Name: J82

Synonyms: J-82, J 82, J82COT, J82 COT, J82 CO'T, J82/WT

Cross References: BTO:BTO_0001671, CLO:CLO_0007006, EFO:EFO_0002210,

MCCL:MCC:0000253, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-1, BioSample:SAMN03471085, BioSample:SAMN10987788, cancercellines:CVCL_0359, CCRID:1101HUM-PUMC000346, CCRID:3101HUMTCHu218, CCRID:4201HUM-CCTCC00225, CCTCC:GDC0225, Cell_Model_Passport:SIDM00693, ChEMBL-Cells:ChEMBL3308508, ChEMBL-Targets:ChEMBL614586, CLS:305055, Cosmic:753566, Cosmic:755399, Cosmic:760474, Cosmic:808517, Cosmic:809378, Cosmic:845571, Cosmic:846276, Cosmic:867838, Cosmic:943731, Cosmic:1016887, Cosmic:1046674, Cosmic:1093984, Cosmic:1175827, Cosmic:1285119, Cosmic:1285996, Cosmic:1302362, Cosmic:1927308, Cosmic:1995459, Cosmic:2050445, Cosmic:2057450, Cosmic:2444229, Cosmic:2686097, Cosmic:2700997, Cosmic-CLP:753566, DepMap:ACH-000396, EGA:EGAS00001000978, GDSC:753566, GEO:GSM136231, GEO:GSM492491, GEO:GSM827204, GEO:GSM887167, GEO:GSM888239, GEO:GSM1374575, GEO:GSM1574579, GEO:GSM1669946, IARC_TP53:3721, IARC_TP53:21416, IGRhCellID:J82, KCB:KCB 2014052YJ, KCLB:30001, LiGeA:CCLE_551, LINCS_LDP:LCL-1714, PharmacoDB:J82_675_2019, PRIDE:PXD030304, PRIDE:PXD032049, Progenetix:CVCL_0359, PubChem_Cell_line:CVCL_0359, Wikidata:Q54898490

ID: CVCL_0359

Record Creation Time: 20250131T201054+0000

Record Last Update: 20250131T202549+0000

Ratings and Alerts

No rating or validation information has been found for J82.

No alerts have been found for J82.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Okholm TLH, et al. (2024) circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA. eLife, 13.

Mann J, et al. (2024) Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. *International journal of cancer*.

Kawahara I, et al. (2024) Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. *Molecular oncology*, 18(9), 2196.

Lammert FC, et al. (2024) Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes. *Molecular oncology*, 18(6), 1397.

Hernández-Prat A, et al. (2024) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. *Molecular oncology*.

Dressler FF, et al. (2024) Proteomic analysis of the urothelial cancer landscape. *Nature communications*, 15(1), 4513.

Chen H, et al. (2024) circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA. *iScience*, 27(4), 109624.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Yan Y, et al. (2024) IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. *Cancer cell international*, 24(1), 386.

Kim B, et al. (2023) Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer. *International journal of cancer*, 152(2), 320.

Wang Z, et al. (2023) Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event. *iScience*, 26(12), 108482.

Ni Z, et al. (2022) JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. *Cancer research*, 82(9), 1789.

Schuhwerk H, et al. (2022) The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. *Cell reports*, 41(11), 111819.

Lu YT, et al. (2022) FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. *Cancers*, 14(7).

Wu Z, et al. (2022) Prognostic significance of SNCA and its methylation in bladder cancer.

BMC cancer, 22(1), 330.

Xu T, et al. (2022) Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Scientific reports, 12(1), 5518.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer cell, 40(9), 1027.

Wang Y, et al. (2022) Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. Cancer research, 82(6), 1128.

Liu Z, et al. (2020) Paris polyphylla ethanol extract induces G2/M arrest and suppresses migration and invasion in bladder cancer. Translational cancer research, 9(10), 5994.